Advertisement

Topics

STA-21 Topical Efficacy on Psoriasis

2014-08-27 03:16:41 | BioPortfolio

Summary

The clinical assessment of patients with plaque-type psoriasis is performed by open, intrapatient comparison of 0.2% STA-21 with vehicle(Vaseline) alone within a 2 week period.

Description

Two discrete psoriatic lesions with a similar size (approximately coin-sized) and clinical severity are selected in each patient. Clinical assessment of psoriatic lesion severity is performed at the baseline and at 1 and 2 (end of treatment) using the scores of erythema, induration, scaling on a scale of 0-4 by two observers. Since STA-21 inhibits Stat3 activation, which is essential for disease activity of psoriasis, topical application of 0.2% STA-21 in Vaseline should improve psoriasis in two weeks.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Conditions

Psoriasis

Intervention

Topical application of STA-21 ointment for treatment of psoriasis

Location

Department of Dermatology, Kochi Medical School, Kochi University
Nankoku
Japan
783-8505

Status

Completed

Source

Kochi University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:16:41-0400

Clinical Trials [1924 Associated Clinical Trials listed on BioPortfolio]

A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test

To investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations of AN2728 in patients with psoriasis vulgaris

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

The purpose of this trial is to compare the anti-psoriatic effect of a topical combination product containing clobetasol propionate and calcipotriol in an ointment formulation to the singl...

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with...

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

Evaluation of safety, pharmacokinetics, and anti-psoriatic efficacy to assess SOR007 Ointment in topical formulations

Treatment of Psoriasis With Parathyroid Hormone

This is a clinical study in two phases. The first phase compares the effect of an ointment containing parathyroid hormone (PTH) with the effect of a placebo ointment (inactive ointment wit...

PubMed Articles [21531 Associated PubMed Articles listed on BioPortfolio]

Therapeutic equivalence of two formulations of calcipotriol-betamethasone ointment: a multi-centre, randomized, double-blind study in adult patients with chronic plaque psoriasis.

Topical agents are the first-line therapy for psoriasis and treatment of choice for mild to moderate chronic plaque psoriasis. Patients with severe psoriasis often use topical therapies at least for s...

The Evolution of Topical Formulations in Psoriasis.

Most people with mild-to-moderate psoriasis manage their disease with topical therapies. However, adherence to topical treatment remains a challenge, as the daily application creates a significant tre...

Scalp psoriasis: report of efficient treatment with secukinumab.

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population in the world. The scalp is the most common, and frequently the first site of disease involvement. Occasionally it may ...

Emerging landscape in psoriasis management: From topical application to targeting biomolecules.

Psoriasis is a chronic autoimmune skin disorder affecting 2-3% of the world population. It has characteristic features such as increased keratinocyte proliferation and production of inflammatory media...

Treatment of Genital Psoriasis: A Systematic Review.

Genital psoriasis affects approximately 63% of psoriasis patients at least once in their lifetime. More than any other area on the body, genital lesions significantly impair patients' psychologic well...

Medical and Biotech [MESH] Definitions

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A by-product of the destructive distillation of coal used as a topical antieczematic. It is an antipruritic and keratoplastic agent used also in the treatment of psoriasis and other skin conditions. Occupational exposure to soots, tars, and certain mineral oils is known to be carcinogenic according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985) (Merck Index, 11th ed).

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

More From BioPortfolio on "STA-21 Topical Efficacy on Psoriasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Mirvaso (brimonidine)
MIRVASO® (BRIMONIDINE) TOPICAL GEL, 0.33%* IS THE FIRST & ONLY FDA-APPROVED TREATMENT DEVELOPED AND INDICATED FOR PERSISTENT FACIAL REDNESS OF ROSACEA Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for th...


Searches Linking to this Trial